INSIDER
:strip_exif(true):strip_icc(true):no_upscale(true):quality(65)/d1vhqlrjc8h82r.cloudfront.net/10-15-2021/t_58b66898734140239a1c80396843cae2_name_image.jpg)
FDA advisory committee votes to approve Johnson & Johnson vaccine booster shots
Read full article: FDA advisory committee votes to approve Johnson & Johnson vaccine booster shotsThe outside panel of experts voted unanimously in favor of offering booster doses of the Johnson & Johnson vaccine at least two months after the first dose.
:strip_exif(true):strip_icc(true):no_upscale(true):quality(65)/d1vhqlrjc8h82r.cloudfront.net/10-14-2021/t_8014ee7d92c1485da4960d19812ec21a_name_image.jpg)
FDA advisory committee votes to approve Moderna vaccine booster shots for vulnerable groups
Read full article: FDA advisory committee votes to approve Moderna vaccine booster shots for vulnerable groupsThe outside panel of experts voted unanimously in favor of offering Moderna boosters to specific groups of people, at least six months after their second dose.
:strip_exif(true):strip_icc(true):no_upscale(true):quality(65)/d1vhqlrjc8h82r.cloudfront.net/10-12-2021/t_1a67b1c664184a04bda9a6ab9cb1015f_name_image.jpg)
FDA advisory panel to meet on Moderna, Johnson & Johnson COVID vaccine booster shots
Read full article: FDA advisory panel to meet on Moderna, Johnson & Johnson COVID vaccine booster shotsThe Food and Drug Administration’s vaccine advisory panel is set to meet Thursday and Friday, Oct. 14-15, and we are getting our first look at the data the panel will be using to make its recommendation on booster shots for Moderna and Johnson & Johnson.
:strip_exif(true):strip_icc(true):no_upscale(true):quality(65)/d1vhqlrjc8h82r.cloudfront.net/08-17-2021/t_b145f00eec2a47689a98134c11c3bd1f_name_image.jpg)
:strip_exif(true):strip_icc(true):no_upscale(true):quality(65)/d1vhqlrjc8h82r.cloudfront.net/08-12-2021/t_abc420b29cd74c11bee6bcf5621e38de_name_image.jpg)
COVID vaccine ‘booster’ dose to be authorized for immunocompromised individuals
Read full article: COVID vaccine ‘booster’ dose to be authorized for immunocompromised individualsStudies found that many immunocompromised people who didn’t respond to the first two doses of a COVID vaccine can benefit from a third dose.